Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Ionis Pharmaceuticals

IONSNasdaqWilmington, US-DE, USMid cap
  • Russell 1000

What Ionis Pharmaceuticals is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $0.87 billion, down 7.4% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$0.56 billion.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.06 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
  • Latest earnings call or results release (July 29, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
  • Guidance in the last 90 days: 0 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 26, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $2.5 million on the open market.SEC Form 4
  • 514 institutional managers reported a position at June 30, 2026 (+18 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 3 (3 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Ionis Pharmaceuticals yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Ionis Pharmaceuticals: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

−$0.56BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: revenue, trailing twelve months

$ billions, from SEC filings

$0.9BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Ionis Pharmaceuticals: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.00BData to Dec 2022
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2019
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: debt maturity schedule, latest annual report

Scheduled repayments of long-term debt principal by year from the fiscal year end, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

−31.6Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Ionis Pharmaceuticals: guidance raised minus lowered

Guidance Ledger statements by quarter

0.0Data to Jun 2026
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Ionis Pharmaceuticals: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.70Data to Jul 2026
ImageDataPalanor calculation
Business

Ionis Pharmaceuticals: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Jul 2026
ImageDataPalanor calculation
Business

Ionis Pharmaceuticals: risk factors added per annual report

New Item 1A risk factors in each 10-K

1.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Ionis Pharmaceuticals: H-1B filings certified

Labor Condition Applications by quarter received

3.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Ionis Pharmaceuticals: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$2.5MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ionis Pharmaceuticals: institutional holders

Managers reporting a position on Form 13F, by quarter

514.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Patent
    Patent granted: Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofUS 12767948
  2. Oct 19, 2026Lobbying
    Lobbying report (LMH STRATEGIC SOLUTIONS)third_quarter 2026 · $0.0 million
  3. Oct 15, 2026Lobbying
    Lobbying report (IONIS PHARMACEUTICALS, INC.)third_quarter 2026 · $0.1 million
  4. Sep 29, 2026Patent
    Patent granted: SYNTHESIS OF OLIGOMERIC COMPOUNDS COMPRISING PHOSPHOROTHIOATE DIESTER AND PHOSPHODIESTER LINKAGESUS 12747260
  5. Sep 22, 2026Patent
    Patent granted: COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSIONUS 12742170
  6. Sep 15, 2026Patent
    Patent granted: COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSIONUS 12735700
  7. Jul 17, 2026Lobbying
    Lobbying report (IONIS PHARMACEUTICALS, INC.)second_quarter 2026 · $0.1 million
  8. Jul 6, 2026Trademark
    Trademark application: THAT FEELING WHEN
  9. Jul 6, 2026Trademark
    Trademark application: OUT OF THE DANGER ZONE
  10. Jul 5, 2026Lobbying
    Lobbying report (LMH STRATEGIC SOLUTIONS)second_quarter 2026 · $0.0 million
  11. Jun 24, 2026Trademark
    Trademark application: LET'S TALK TRIGLYCERIDES
  12. Jun 24, 2026Trademark
    Trademark application: EXPAND WHAT'S POSSIBLE IN TRIGLYCERIDE REDUCTION
  13. Jun 23, 2026Patent
    Patent granted: COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSIONUS 12662508
  14. Jun 8, 20268-K
    Director or officer changeItem 5.02
  15. Jun 8, 20268-K
    Shareholder vote resultsItem 5.07
  16. Apr 28, 2026Trademark
    Trademark application: KNOW YOUR TRIGLYCERIDES
  17. Apr 17, 2026Lobbying
    Lobbying report (LMH STRATEGIC SOLUTIONS)first_quarter 2026 · $0.0 million
  18. Apr 9, 2026Lobbying
    Lobbying report (IONIS PHARMACEUTICALS, INC.)first_quarter 2026 · $0.1 million
  19. Mar 9, 20268-K
    Director or officer changeItem 5.02
  20. Feb 26, 202610-K
    Annual report (10-K)1 risk factors added, 0 removed
  21. Jan 18, 2026Lobbying
    Lobbying report (IONIS PHARMACEUTICALS, INC.)fourth_quarter 2025 · $0.1 million
  22. Jan 12, 2026Lobbying
    Lobbying report (LMH STRATEGIC SOLUTIONS)fourth_quarter 2025 · $0.1 million
  23. Nov 17, 20258-K
    Material agreement signedItem 1.01
  24. Nov 3, 20258-K
    Material agreement signedItem 1.01
  25. Jun 12, 20258-K
    Director or officer changeItem 5.02
  26. Jun 10, 20258-K
    Shareholder vote resultsItem 5.07
  27. Mar 12, 20258-K
    Material agreement signedItem 1.01
  28. Feb 19, 202510-K
    Annual report (10-K)0 risk factors added, 0 removed
  29. Feb 21, 202410-K
    Annual report (10-K)1 risk factors added, 1 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Corcept Therapeutics CORT$0.8B$0.1BJun 30, 2026
Repligen RGEN$0.8B$0.1BJun 30, 2026
Axsome Therapeutics AXSM$0.8B−$0.1BJun 30, 2026
Caris Life Sciences CAI$1.0B$0.1BJun 30, 2026
BridgeBio Pharma BBIO$0.7B−$0.4BJun 30, 2026
Arrowhead Pharmaceuticals ARWR$0.7B−$0.1BJun 30, 2026
Insmed INSM$1.1B−$0.8BJun 30, 2026
Doximity DOCS$0.7B—Jun 30, 2026

Identity

SEC CIK
874015
LEI
549300SI4ZGLG0BLUZ92

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.